Krishna Institute of Medical Sciences (KIMS) investor relations material

Executive summary

• Revenue grew 35.3% year-over-year in Q4 FY26 to INR 1,084 crore, with full-year revenue up 28.6% to INR 3,931 crore (₹39,046 million), reflecting strong operational excellence and strategic expansion.

• EBITDA margin declined to 19.9% in Q4 FY26 from 25.3% a year ago; full-year margin at 21.1% vs 26.6% last year.

• Net cash position decreased to INR 33 crore in Q4 FY26 from INR 106 crore in Q4 FY25.

• EPS for FY26 dropped 37.3% year-over-year to INR 6.03.

• Audited standalone and consolidated financial results for FY26 were approved, with unmodified audit opinions issued by statutory auditors.

Financial highlights

• Q4 EBIT was INR 216 crore, up 6.8% year-over-year and 5.9% sequentially.

• FY26 EBITDA rose to ₹8,282 million, up 1.6% year-over-year; PAT for FY26 was ₹2,420 million, down 41.7% year-over-year.

• Consolidated EBITDA pre Ind AS for Q4 was INR 131 crore, down 33.5% year-over-year.

• ARPOB increased 14% year-over-year to ₹44,644 in FY26; ARPP rose 11.4% to ₹1,59,575.

• Occupancy rate remained stable at 50.5% in FY26 despite significant bed additions.

Outlook and guidance

• Margin expansion expected cluster-wise as new units mature; EBITDA drag from new units to reduce by more than half next year.

• Adding 1,300+ beds through greenfield projects, acquisitions, and O&M opportunities to drive future growth.

• Thane and Mahadevapura expected to reach EBITDA positive within 12 months of commissioning; Electronic City by end of FY27.

• Telangana cluster expected to see 10-12% EBITDA growth in FY27.

• Continued focus on regulatory compliance and monitoring of labor code changes.